Slides on The Nurse’s Expanding Role in Treating Psoriatic Conditions: Improving Outcomes and Patient Satisfaction

Download slides that review guideline recommendations for assessing and improving quality of life in patients with psoriasis and psoriatic arthritis with an emphasis on managing comorbidities and selecting optimal therapies.
Lakshi M. Aldredge, MSN, ANP-BC, DCNP
Format: Microsoft PowerPoint (.ppt)
File Size: 1.48 MB
Released: August 20, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AbbVie
Lilly

Related Content

Commentary by Dr. Vinod Chandran on using interleukin inhibitors secukinumab and guselkumab for axial manifestations of psoriatic arthritis, from CCO

Vinod Chandran, MBBS, MD, DM, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 11, 2021 Expired: January 10, 2022

Commentary from Dr Jim Treat on counseling parents and children about pros and cons of systemic therapy for pediatric plaque psoriasis, from CCO

person default Jim Treat, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 8, 2021 Expired: January 7, 2022

CME for CCO on when to use interleukin inhibitors in psoriatis arthritis: biologic DMARD or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab

Vinod Chandran, MBBS, MD, DM, PhD person default Alexis Ogdie, MD, MSCE Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: December 29, 2020 Expired: December 28, 2021

CCO slides on when to use interleukins inhibitors in psoriatis arthritis: biologic dmard or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab.

Vinod Chandran, MBBS, MD, DM, PhD person default Alexis Ogdie, MD, MSCE Released: December 29, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue